Álvaro González-Franco

Álvaro González-Franco

Auto-generated profile, based on publicly available information

Álvaro González-Franco

Servicio de Medicina Interna, Hospital Universitario Central de Asturias, Oviedo, Spain

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Revista Clínica Española
Verified
Journal Article
Closed access
JCJ.M. Cerqueiro
J.M. Cerqueiro
AGA. González-Franco
A. González-Franco
MMM. Montero-Pérez-Barquero
M. Montero-Pérez-Barquero
PLP. Llácer
P. Llácer
ACAlicia Conde-Martel
Alicia Conde-Martel
LMLuis Manzano
Luis Manzano

1 January 2017 in Revista Clínica Española
Verified
Journal Article
Closed access
NMN. Manito
N. Manito
JCJ.M. Cerqueiro
J.M. Cerqueiro
JCJ. Comín-Colet
J. Comín-Colet
JGJ.M. García-Pinilla
J.M. García-Pinilla
AGA. González-Franco
A. González-Franco
LMLuis Manzano
Luis Manzano

1 October 2015 in Revista Clínica Española
Verified
Journal Article
Closed access
ACAlicia Conde-Martel
Alicia Conde-Martel
MAM.E. Arkuch
M.E. Arkuch
FFFrancesc Formiga
Francesc Formiga
LMLuis Manzano
Luis Manzano
OAO. Aramburu-Bodas
O. Aramburu-Bodas
MMM. Montero-Pérez-Barquero
M. Montero-Pérez-Barquero

1 May 2018 in Medicina Clinica
Verified
Journal Article
Closed access
JFJonathan Franco
Jonathan Franco
FFFrancesc Formiga
Francesc Formiga
JCJose Cepeda
Jose Cepeda
PLPau Llacer
Pau Llacer
JAJuan Arévalo-Lorido
Juan Arévalo-Lorido
MPManuel Montero Pérez-Barquero
Manuel Montero Pérez-Barquero

23 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MMManuel Méndez-Bailón
Manuel Méndez-Bailón
NVNoel Lorenzo Villalba
Noel Lorenzo Villalba
ÁGÁlvaro González-Franco
Álvaro González-Franco
LMLuis Manzano
Luis Manzano
JCJesús Casado-Cerrada
Jesús Casado-Cerrada
MMManuel Montero-Perez-Barquero
Manuel Montero-Perez-Barquero
Background: Individuals suffering from heart failure (HF) and cardiorenal syndrome (CRS) represent a special group of patients considering their age, multiple health issues, and treatment challenges. These factors make them more susceptible to frequent hospital stays and a higher mortality rate. UMIPIC is a multidisciplinary care model program for patients with heart failure follow up provided by internists and nurses who are experts in this entity. Our study delved into the effectiveness of this specialized care program (UMIPIC) in mitigating these risks for HF and CRS patients. Methods: We analyzed the medical records of 3255 patients diagnosed with HF and CRS types 2 and 4, sourced from the RICA registry. These patients were divided into two distinct groups: those enrolled in the UMIPIC program (1205 patients) and those under standard care (2050 patients). Using propensity score matching, we ensured that both groups were comparable. The study focused on tracking hospital admissions and mortality rates for one year after an HF-related hospital stay. Results: Patients in the UMIPIC group experienced fewer hospital readmissions due to HF compared to their counterparts (20% vs. 32%; Hazard Ratio [HR] = 0.48; 95% Confidence Interval [95% CI]: 0.40–0.57; p < 0.001). They also showed a lower mortality rate (24% vs. 36%; HR = 0.64; 95% CI: 0.54–0.75; p < 0.001). Furthermore, the UMIPIC group had fewer total hospital admissions (36% vs. 47%; HR = 0.58; 95% CI: 0.51–0.66; p < 0.001). Conclusions: The UMIPIC program, centered on holistic and ongoing care, effectively reduces both hospital admissions and mortality rates for HF and CRS patients after a one-year follow-up period.

30 October 2020 in Journal of Medical Economics
Verified
Journal Article
Open access
Juan F. Delgado JiménezJuan F. Delgado Jiménez
Juan F. Delgado Jiménez
JOJuan Oliva-Moreno
Juan Oliva-Moreno
ÁGÁlvaro González-Franco
Álvaro González-Franco
JCJose María Cepeda
Jose María Cepeda
JGJose Angel Garcia Garcia
Jose Angel Garcia Garcia
JCJosep Comín-Colet
Josep Comín-Colet
Objective The treatment of iron deficiency (ID) with ferric carboxymaltose (FCM) improves the functional class and quality of life of chronic heart failure (CHF) patients with reduced left ventricular ejection fraction (LVEF), and reduces the rate of hospitalization due to worsening CHF. This study aims to evaluate the budget impact for the Spanish National Health System (SNHS) of treating ID in reduced LVEF CHF with FCM compared to non-iron treatment. Methods We simulated a hypothetical cohort of 1000 CHF patients with ID and reduced LVEF based on the Spanish population characteristics. A decision-analytic model was also built using the data from the largest FCM clinical trial (CONFIRM-HF) that lasted for a year. We considered the use of healthcare resources from a national prospective study. A deterministic sensitivity analysis was carried out varying the corresponding baseline data by +/- 25%. Results The cost of treating the simulated population with FCM was euro2,570,914, while that of the non-iron treatment was euro3,105,711, which corresponds to a cost saving of euro534,797 per 1,000 patients in one year. Cost savings were mainly due to a decrease in the number of hospitalizations. All sensitivity analysis showed cost savings for the SNHS. Conclusions FCM results in an annual cost saving of euro534.80 per patient, and would thus be expected to reduce the economic burden of CHF in Spain.